Results 131 to 140 of about 144,925 (192)

Metabolomics Effects of Folding Correction in Retinitis Pigmentosa Rhodopsin Mutant P23A. [PDF]

FASEB J
Murthy MHS, Staggs-Sandy H, Jasbi P, Reeves PJ, Klein-Seetharaman J.   +4 more
europepmc   +1 more source

Abiotic synthesis of RNase-resistant phosphodiester and pyrophosphate-linked polymers via thermodynamically controlled wet-dry cycling. [PDF]

Sci Rep
Simonis P, Rheinstädter HV, Masevičius V, Pudritz RE, Bujold KE, Rheinstädter MC.   +5 more
europepmc   +1 more source

Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure. [PDF]

Br J Cancer
Trecourt A, Valent A, Yaniz-Galende E, Rouleau E, Grau Bejar JF, Blanc-Durand F, Edmond E, Le Formal A, Genestie C, Leary A.   +9 more
europepmc   +1 more source

Substrate Specificity of B12-Depedent Ribonucleotide Reductases: Biotechnology and Metabolic Implications. [PDF]

Chembiochem
Eltoukhy L, Loderer C.
europepmc   +1 more source

The molecular basis of ADP-ribose pyrophosphorylation by a phage PRPS-like enzyme in NAD+ reconstitution. [PDF]

Nucleic Acids Res
Liu M, Ma J, Zhang Q, Xu S, Chen J, Lin E, Wu Y, Li H, Zhou B, Chen L.   +9 more
europepmc   +1 more source

Studies on poly(adenosine diphosphate ribose). IX. Direction of hydrolysis of poly(adenosine diphosphate ribose) by rat liver phosphodiesterase.

The Journal of biological chemistry, 1971
H, Matsubara, S, Hasegawa, S, Fujimura, T, Shima, T, Sugimura   +4 more
openaire   +1 more source

Comment on "<i>PARP-1</i> rs1136410 Polymorphism and Gastrointestinal Cancer Risk: A Meta-Analysis of Cancer-Type and Ethnic-Specific Associations". [PDF]

Medeni Med J
Alkan O, Nazli I, Basgoze A.
europepmc   +1 more source

Studies on poly (adenosine diphosphate ribose). V. Mechanism of hydrolysis of poly (adenosine diphosphate ribose) by snake venom phosphodiesterase.

The Journal of biological chemistry, 1970
H, Matsubara, S, Hasegawa, S, Fujimura, T, Shima, T, Sugimura   +4 more
openaire   +1 more source

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA Oncol
Haggstrom L, Lee YC, Barretina-Ginesta MP, Jaeger A, Woelber L, Woopen H, Rhind M, Frenel JS, Aanum A, Bischof K, Mongillo M, Brodsky AL, Ledermann J, Ghezelayagh TS, Boere I, Kaiser S, Maximiano C, Rosengarten O, Safra T, Pertejo A, Cecere S, Ray-Coquard I, Lheureux S, Glasspool R, Gil-Martin M, Tookman L, Kim SI, Mittelstadt S, Corbellas Aparicio M, Palacio I, Martin-Lorente C, Kristeleit R, de la Cueva H, Ottevanger N, Quindós Varela M, Yoshida H, Link T, Gaba L, Marquina G, Burdett N, Johannet P, Reichenbach J, Park-Simon TW, Klecker PH, González-Martín A, Marth C, Liebrich C, Dzotsenidze L, Heublein S, Kasherman L, Perez C, Masvidal M, Guillén Sentís P, de Gregorio N, Hemptenmacher F, Hilpert F, Sehouli J, Scott C, Tucker KM, Dong J, Fortuno C, Spurdle AB, Friedlander M, Gynecologic Cancer InterGroup Collaboration Into Exceptional Responders to PARP Inhibitors (GCIG-CERP).   +63 more
europepmc   +1 more source

Emerging Roles of Adenosine Metabolism in Astrocytes During Brain Injury. [PDF]

CNS Neurosci Ther
Zhu S, Zhong S, Lin X, Zhao C, Li Y.
europepmc   +1 more source